 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Minyoung] Osstem Implant, which was acquired by domestic private equity firms MBK Partners and UCK Partners, is pushing to acquire 'ZimVie', a dental implant company listed on the Nasdaq. This follows the acquisition of a Brazilian implant company in April and is seen as a strategy to accelerate global market expansion through the acquisition of a North American company.
According to Bloomberg and other local media reports on the 22nd, Osstem Implant is in negotiations for the acquisition of ZimVie and has reportedly submitted a final bid.
Details regarding the stake and size of the acquisition have not been disclosed. As of the 17th, ZimVie's market capitalization was $517 million (approximately 718 billion KRW), but it has surged to around $595 million (approximately 826 billion KRW) following the spread of acquisition news.
ZimVie was spun off from the American medical device company Zimmer Biomet Holdings in 2022. It employs over 1,800 people in the United States, Switzerland, China, and other locations. In April, ZimVie sold its spine-related business to H.I.G. Capital for $375 million and has since focused on its implant business. Last year, ZimVie recorded sales of approximately 635 billion KRW and an operating loss of about 42.9 billion KRW.
The investment banking industry sees Osstem Implant's acquisition of ZimVie as part of its accelerated global market expansion strategy after being acquired by the MBK Partners and UCK Partners consortium last year. This move is analyzed as part of a 'bolt-on' strategy, which aims to achieve rapid growth through the acquisition of related local companies.
AlphaBIZ Kim Minyoung(kimmy@alphabiz.co.kr)
